Celator Pharmaceuticals Inc (NASDAQ:CPXX) Announces Initial Results of Phase III Study Of CPX-351


Dallas, Texas 06/25/2015 (Financialstrend) – Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced early reports from the CPX-351 clinical study. The study is aimed at finding out the efficiency of a new approach of medical treatment of patients with secondary a0 to acute myeloid leukemia. The report gives indication of success compared to conventional methods of medical treatment.

The Study of CPX-351

Celator Pharmaceuticals Inc (NASDAQ:CPXX) began the study in December 2012 with the cooperation of Leukemia and Lymphoma Society (LLS). The study involved 309 patients. Around 39 clinical centers were selected across the United States and Canada. The study was randomized with 50% patients receiving CPX-351 and rest of the 50% receiving the standard cytarabine and daunorubicin (7+3), aka conventional chemotherapy.

The efficacy standards were set, the primary efficacy endpoint being the overall survival. Secondary endpoints included complete response rate, duration of remission, 30 and 60 day mortality, event-free survival and rate of stem cell transplant.

The Initial Results and Further Study

Celator Pharmaceuticals Inc (NASDAQ:CPXX) declared the induction response rate of CPX-351. The patients were of the ages between 60 to 75 years. The induction response rate in case of CPX-351 was found to be 47.7%. This is an improvement over the traditional 7+3 regimen which registered the rate of 33.3%.

This relative improvement of 43.2% is certainly looking good for CPX-351. However, much of the study is yet to be done. The results for overall survival are expected in the first quarter of 2016. Much of the data is expected to be released at the end of the study.

Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced that the current result for the induction rate is satisfying. It is believed that induction response rate is a contributing factor in overall survival rate. The CPX-351 will most probably be presented to FDA in 2016 or 2017 for approval.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.